Trial Profile
A Single-masked, Randomized, Multi-center, Parallel-group, 4-week Study Evaluating the Efficacy and Safety of Once Daily Netarsudil Ophthalmic Solution 0.02% Compared to Twice Daily Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% in Japanese Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Aug 2023
Price :
$35
*
At a glance
- Drugs Netarsudil (Primary) ; Ripasudil
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Registrational; Therapeutic Use
- Acronyms J-ROCKET
- Sponsors Aerie Pharmaceuticals
- 12 Aug 2023 Results published in the Advances in Therapy
- 12 Oct 2021 Primary endpoint of Intraocular Pressure has been met, according to an Aerie Pharmaceuticals media release.
- 12 Oct 2021 Results presented in an Aerie Pharmaceuticals media release.